DeutschNewstral
Article
jdsupra.com on 2020-03-23 23:22
Biosimilars Development Updates: Mylan’s Pipeline, Coherus’s Adalimumab aBLA, Amgen’s Eculizumab Biosimilar
Related news
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- FDA Approves Mylan’s Biosimilar of HUMIRA (Adalimumab)jdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- European Biosimilar Approval Updates: Adalimumab, Pegfilgrastimjdsupra.com
- Sandoz Launches Adalimumab Biosimilar in Spainjdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilarsjdsupra.com
- Biosimilar Pipeline Updatejdsupra.com
- Pfizer Moves to Dismiss Amgen’s Suit Over Proposed Neulasta Biosimilarjdsupra.com
- FDA Advisory Committee to Hold Public Meetings on Amgen’s Proposed Bevacizumab Biosimilar and Mylan’s Proposed Trastuzumab Biosimilarjdsupra.com
- AbbVie and Fresenius Kabi Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- U.S. Biosimilar Regulatory and Launch Updates: Adalimumab, Filgrastimjdsupra.com
- Paper reports on administration of adalimumab biosimilar using an autoinjectorjdsupra.com
- AbbVie and Sandoz Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- Biosimilar Pipeline Developments: Rituximab, Adalimumab, Eculizumab, Infliximab, Pegfilgrastimjdsupra.com
- Biosimilar and Biologic Updates in China: Bevacizumab, Etanercept, Tislezumab, Infliximab, Eculizumab, Adalimumabjdsupra.com
- Litigation Update: Genentech’s Motion to Dismiss Amgen’s Counterclaims Denied in Avastin Biosimilar Litigationjdsupra.com
- Prosecution History Estoppel Bars Amgen’s Doctrine-of-Equivalents Infringement Claim Against Neulasta (Pegfilgrastim) Biosimilar Maker Coherusjdsupra.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilars (Updated)jdsupra.com
- Boehringer Ingelheim Announces Positive Phase III Results for Its Adalimumab Biosimilarjdsupra.com